156 related articles for article (PubMed ID: 1373347)
1. IGF binding protein 3 in patients with Laron type dwarfism: effect of exogenous rIGF-I.
Laron Z; Klinger B; Blum WF; Silbergeld A; Ranke MB
Clin Endocrinol (Oxf); 1992 Mar; 36(3):301-4. PubMed ID: 1373347
[TBL] [Abstract][Full Text] [Related]
2. Long-term treatment of Laron type dwarfs with insulin-like growth factor-1 increases serum insulin-like growth factor-binding protein-3 in the absence of growth hormone activity.
Kanety H; Karasik A; Klinger B; Silbergeld A; Laron Z
Acta Endocrinol (Copenh); 1993 Feb; 128(2):144-9. PubMed ID: 7680834
[TBL] [Abstract][Full Text] [Related]
3. Growth hormone and insulin-like growth factor regulate insulin-like growth factor-binding protein-1 in Laron type dwarfism, growth hormone deficiency and constitutional short stature.
Laron Z; Suikkari AM; Klinger B; Silbergeld A; Pertzelan A; Seppälä M; Koivisto VA
Acta Endocrinol (Copenh); 1992 Oct; 127(4):351-8. PubMed ID: 1280392
[TBL] [Abstract][Full Text] [Related]
4. Growth hormone insensitivity syndromes: a preliminary report on changes in insulin-like growth factors and their binding proteins during treatment with recombinant insulin-like growth factor I. Kabi Pharmacia Study Group on Insulin-like Growth Factor I Treatment in Growth Hormone Insensitivity Syndromes.
Blum WF; Hall K; Ranke MB; Wilton P
Acta Paediatr Suppl; 1993 Sep; 82 Suppl 391():15-9. PubMed ID: 7693071
[TBL] [Abstract][Full Text] [Related]
5. Biochemical and hormonal changes induced by one week of administration of rIGF-I to patients with Laron type dwarfism.
Laron Z; Klinger B; Jensen LT; Erster B
Clin Endocrinol (Oxf); 1991 Aug; 35(2):145-50. PubMed ID: 1934530
[TBL] [Abstract][Full Text] [Related]
6. The effect of recombinant human insulin-like growth factor-I treatment on growth hormone secretion in two subjects with growth hormone insensitivity (Laron syndrome).
Cotterill AM; Camacho-Hübner C; Holly JM; Savage MO
Clin Endocrinol (Oxf); 1993 Jul; 39(1):119-22. PubMed ID: 7688671
[TBL] [Abstract][Full Text] [Related]
7. Effects of exogenous insulin-like growth factor I on insulin-like growth factor binding proteins in a case of growth hormone insensitivity (Laron-type).
Gourmelen M; Perin L; Binoux M
Acta Paediatr Scand Suppl; 1991; 377():115-7. PubMed ID: 1723834
[TBL] [Abstract][Full Text] [Related]
8. Treatment with recombinant human insulin-like growth factor I of children with growth hormone receptor deficiency (Laron syndrome). Kabi Pharmacia Study Group on Insulin-like Growth Factor I Treatment in Growth Hormone Insensitivity Syndromes.
Wilton P
Acta Paediatr Suppl; 1992 Sep; 383():137-42. PubMed ID: 1281024
[TBL] [Abstract][Full Text] [Related]
9. Insulin-like growth factor-I raises serum procollagen levels in children and adults with Laron syndrome.
Klinger B; Jensen LT; Silbergeld A; Laron Z
Clin Endocrinol (Oxf); 1996 Oct; 45(4):423-9. PubMed ID: 8959080
[TBL] [Abstract][Full Text] [Related]
10. The insulin-like growth factor (IGF)-binding proteins and IGF bioactivity in Laron-type dwarfism.
Cotterill AM; Holly JM; Taylor AM; Davies SC; Coulson VJ; Preece MA; Wass JA; Savage MO
J Clin Endocrinol Metab; 1992 Jan; 74(1):56-63. PubMed ID: 1370165
[TBL] [Abstract][Full Text] [Related]
11. Long-term effects of insulin-like growth factor (IGF)-I on serum IGF-I, IGF-binding protein-3 and acid labile subunit in Laron syndrome patients with normal growth hormone binding protein.
Kanety H; Silbergeld A; Klinger B; Karasik A; Baxter RC; Laron Z
Eur J Endocrinol; 1997 Dec; 137(6):626-30. PubMed ID: 9437227
[TBL] [Abstract][Full Text] [Related]
12. Serum GH binding protein activities identifies the heterozygous carriers for Laron type dwarfism.
Laron Z; Klinger B; Erster B; Silbergeld A
Acta Endocrinol (Copenh); 1989 Oct; 121(4):603-8. PubMed ID: 2800930
[TBL] [Abstract][Full Text] [Related]
13. Effect of acute administration of insulin-like growth factor I in patients with Laron-type dwarfism.
Laron Z; Klinger B; Erster B; Anin S
Lancet; 1988 Nov; 2(8621):1170-2. PubMed ID: 2903379
[TBL] [Abstract][Full Text] [Related]
14. Laron syndrome due to a post-receptor defect: response to IGF-I treatment.
Laron Z; Klinger B; Eshet R; Kaneti H; Karasik A; Silbergeld A
Isr J Med Sci; 1993 Dec; 29(12):757-63. PubMed ID: 8300382
[TBL] [Abstract][Full Text] [Related]
15. Levels of growth hormone, insulin-like growth factor-I (IGF-I) and -II, IGF-binding protein-1 and -3, and cortisol in prednisone-treated children with growth retardation after renal transplantation.
Hokken-Koelega AC; Stijnen T; de Muinck Keizer-Schrama SM; Blum WF; Drop SL
J Clin Endocrinol Metab; 1993 Oct; 77(4):932-8. PubMed ID: 7691864
[TBL] [Abstract][Full Text] [Related]
16. Laron-type dwarfism with apparently normal high affinity serum growth hormone-binding protein.
Buchanan CR; Maheshwari HG; Norman MR; Morrell DJ; Preece MA
Clin Endocrinol (Oxf); 1991 Aug; 35(2):179-85. PubMed ID: 1934534
[TBL] [Abstract][Full Text] [Related]
17. IGF-I and IGF-binding protein-3 in plasma of GH-deficient rats.
Butler AA; Gallaher BW; Ambler GR; Gluckman PD; Breier BH
J Endocrinol; 1996 Jul; 150(1):67-76. PubMed ID: 8708564
[TBL] [Abstract][Full Text] [Related]
18. Clinical features and endocrine status in patients with growth hormone insensitivity (Laron syndrome).
Savage MO; Blum WF; Ranke MB; Postel-Vinay MC; Cotterill AM; Hall K; Chatelain PG; Preece MA; Rosenfeld RG
J Clin Endocrinol Metab; 1993 Dec; 77(6):1465-71. PubMed ID: 7505286
[TBL] [Abstract][Full Text] [Related]
19. Failure to increase insulin-like growth factor-I synthesis is involved in the mechanisms of growth retardation of children with inherited liver disorders.
Maghnie M; Barreca A; Ventura M; Tinelli C; Ponzani P; De Giacomo C; Maggiore G; Severi F
Clin Endocrinol (Oxf); 1998 Jun; 48(6):747-55. PubMed ID: 9713564
[TBL] [Abstract][Full Text] [Related]
20. Serum prolactin in patients with Laron-type dwarfism: effect of insulin-like growth factor I.
Silbergeld A; Klinger B; Schwartz H; Laron Z
Horm Res; 1992; 37(4-5):160-4. PubMed ID: 1490658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
